InspireMD, Inc.
InspireMD, Inc. (NSPR) Financial Performance & Income Statement Overview
Analyze InspireMD, Inc. (NSPR) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
InspireMD, Inc. (NSPR) Income Statement & Financial Overview
Explore comprehensive income reports for InspireMD, Inc. NSPR, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $1.78M | $1.53M | $1.95M | $1.81M |
| Cost of Revenue | $1.47M | $1.24M | $1.48M | $1.40M |
| Gross Profit | $313000.00 | $292000.00 | $469000.00 | $414000.00 |
| Gross Profit Ratio | $0.18 | $0.19 | $0.24 | $0.23 |
| R&D Expenses | $3.83M | $4.06M | $3.69M | $3.92M |
| SG&A Expenses | $9.50M | $7.69M | $6.14M | $4.96M |
| Operating Expenses | $13.33M | $11.75M | $9.84M | $8.88M |
| Total Costs & Expenses | $14.80M | $12.99M | $11.32M | $10.27M |
| Interest Income | $0.00 | $294000.00 | $252000.00 | $572000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $98000.00 | $75000.00 | $70000.00 |
| EBITDA | -$13.02M | -$11.36M | -$9.29M | -$8.39M |
| EBITDA Ratio | -$7.32 | -$7.43 | -$4.77 | -$4.64 |
| Operating Income | -$13.02M | -$11.46M | -$9.37M | -$8.46M |
| Operating Income Ratio | -$7.32 | -$7.50 | -$4.81 | -$4.68 |
| Other Income/Expenses (Net) | -$132000.00 | $294000.00 | $252000.00 | $9.03M |
| Income Before Tax | -$13.15M | -$11.17M | -$9.12M | $572000.00 |
| Income Before Tax Ratio | -$7.40 | -$7.30 | -$4.68 | $0.32 |
| Income Tax Expense | $0.00 | $0.00 | $59000.00 | $0.00 |
| Net Income | -$13.15M | -$11.17M | -$9.17M | -$7.89M |
| Net Income Ratio | -$7.40 | -$7.30 | -$4.71 | -$4.36 |
| EPS | -$0.26 | -$0.22 | $0.01 | -$0.16 |
| Diluted EPS | -$0.26 | -$0.22 | $0.01 | -$0.16 |
| Weighted Avg Shares Outstanding | $51.004M | $49.99M | $48.37M | $48.37M |
| Weighted Avg Shares Outstanding (Diluted) | $51.004M | $49.99M | $48.37M | $48.37M |
Financial performance has remained strong, with revenue growing from $1.81M in Q3 2024 to $1.78M in Q2 2025. Gross profit continued to perform well, with margins at 18% in the latest quarter. Operating income reached -$13.02M in Q2 2025, holding a steady -732% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$13.02M. Net income dropped to -$13.15M, keeping EPS at -$0.26. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan